Nav: Home

Curbing malaria resistance with multiple therapies

March 29, 2016

In order to preserve first-line drugs for treating malaria, multiple combination therapies should be deployed within a population to prevent resistance from developing, according to Maciej Boni from the Centre for Tropical Medicine and Global Health, University of Oxford, UK, and colleagues in a Policy Forum article published in this week's PLOS Medicine.

By treating individuals with a combination of drugs that have different mechanisms of action, the chances of a malaria parasite developing the multiple genetic mutations needed to survive exposure to a combination therapy is substantially decreased and the effectiveness of the therapy is prolonged.

Artemisinin combination therapies (ACTs) have been increasingly used to treat malaria since 2005, when they were recommended as first-line treatments for falciparum malaria by the World Health Organization (WHO). However, just two years later, in 2007, evidence of partial resistance to artemisinins appeared at the Thai-Cambodian border manifesting as a prolonged parasite clearance time in patients treated with a standard three-day course of ACT.

While it may be possible to increase the number of active drugs in a combination therapy given to an individual, doing so increases the potential for side effects and costs. An alternative strategy could be to deploy multiple different combination therapies to different individuals within a community. This approach would require malaria parasites to develop four or more mutations in order to survive across successive human hosts, without the need to develop new antimalarial drugs. In their article the authors argue that a policy of implementing multiple first-line combinations should be considered to preserve the drugs used to combat malaria.

The authors conclude, "[w]ith hundreds of millions of malaria cases per year globally, and challenging epidemiological, political, and economic situations in both African and Asian nations, global malaria policy should be looking thirty years into the future to ensure that our best efforts at elimination are not quickly undermined by strongly drug-resistant phenotypes... The conventional clinical focus on the parasites infecting a particular patient is inadequate to the problem of long-term resistance management. The authors emphasize "a need for a more population-based approach to strategic drug resistance prevention in malaria," noting that "The patient is the community, and the community parasite biomass is the infection in need of an effective and well-managed therapy."
Policy Forum


No specific funding was received for this study.

Competing Interests:

We have read the journal's policy and have the following conflicts: NJW is on the Editorial Board of PLOS Medicine. The authors have declared that no other competing interests exist.


Boni MF, White NJ, Baird JK (2016) The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies. PLoS Med 13(3): e1001984. doi:10.1371/journal.pmed.1001984

Author Affiliations:

Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme, Ho Chi Minh City, Vietnam

Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

Mahidol-Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia



Maciej F. Boni
Oxford University Clinical Research Unit
Hospital for Tropical Diseases
190 Ben Ham Tu
Ho Chi Minh CIty, District 5
+84 938 119 606
FAX: +1 509 562 2296


Related Malaria Articles:

Could there be a 'social vaccine' for malaria?
Malaria is a global killer and a world health concern.
Transgenic plants against malaria
Scientists have discovered a gene that allows to double the production of artemisinin in the Artemisia annua plant.
Fighting malaria through metabolism
EPFL scientists have fully modeled the metabolism of the deadliest malaria parasite.
Should we commit to eradicate malaria worldwide?
Should we commit to eradicate malaria worldwide, asks a debate article published by The BMJ today?
Investigational malaria vaccine shows considerable protection in adults in malaria season
An investigational malaria vaccine given intravenously was well-tolerated and protected a significant proportion of healthy adults against infection with Plasmodium falciparum malaria -- the deadliest form of the disease -- for the duration of the malaria season, according to new findings published in the Feb.
Why malaria mosquitoes like people with malaria
Malaria mosquitoes prefer to feed -- and feed more -- on blood from people infected with malaria.
Malaria superbugs threaten global malaria control
A lineage of multidrug resistant P. falciparum malaria superbugs has widely spread and is now established in parts of Thailand, Laos and Cambodia, causing high treatment failure rates for the main falciparum malaria medicines, artemisinin combination therapies (ACTs), according to a study published today in The Lancet Infectious Diseases.
Considering cattle could help eliminate malaria in India
The goal of eliminating malaria in countries like India could be more achievable if mosquito-control efforts take into account the relationship between mosquitoes and cattle, according to an international team of researchers.
Seasonal malaria chemoprevention in Senegalese children lowers overall malaria burden
Giving preventive antimalarial drugs to children up to age 10 during active malaria season reduced the cases of malaria in that age group and lowered the malaria incidence in adults, according to a randomized trial carried out in Senegal and published in PLOS Medicine by researchers from the Université Cheikh Anta Diop, Senegal, the London School of Hygiene & Tropical Medicine, UK, and other collaborators.
How malaria fools our immune system
OIST researchers reconstruct the 3-D structure of a malaria protein in combination with human antibodies.

Related Malaria Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...